United Therapeutics Corporation (NASDAQ:UTHR) stock price target upped to $137.00, released a report earlier today by Zacks Investment Research
- Updated: October 2, 2016
Stating a possible upside of 0.17%, Zacks Investment Research increased the target price of United Therapeutics Corporation (NASDAQ:UTHR) to $137.00
Yesterday United Therapeutics Corporation (NASDAQ:UTHR) traded 2.66% higher at $116.97. UTHR’s 50-day average is $123.53 and its two hundred day average is $115.94. With the last stock price close up 1.84% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Volume of trade was up over the average, with 738,654 shares of UTHR changing hands over the typical 553,483
See Chart Below
United Therapeutics Corporation has a price-earnings ratio of 5.71 with a one year low of $97.52 and a one year high of $164.04 United Therapeutics Corporation’s market capitalization is currently $0.
A total of 11 equity analysts have released a report on United Therapeutics Corporation. Three analysts rating the stock a strong buy, 3 firms rating the stock a buy, 6 brokers rating the stock a hold, 1 equity analyst rating the company a underperform, and finally 0 brokerages rating the stock a sell with a average stock price target of $140.09.
General Company Details For United Therapeutics Corporation (NASDAQ:UTHR)
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb). Its Prostacyclin Analogues lead product is Remodulin (treprostinil) Injection. It also includes Tyvaso (treprostinil) Inhalation Solution and Orenitram (treprostinil) Extended-Release Tablets. Its subsidiary is developing another oral prostacyclin analogue for the treatment of pulmonary arterial hypertension (PAH) called esuberaprost. Its PDE-5 inhibitor is Adcirca (tadalafil) tablets are indicated for the treatment of PAH. Its Unituxin (dinutuximab) Injection in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2 and 13-cis-retinoic acid is indicated for the treatment of pediatric patients with neuroblastoma.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.